Cancer is one of the leading causes of death. Globally a huge number of deaths and new
incidences are reported annually. Heterocyclic compounds have been proved to be very …

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are effective
targeted therapy drugs for advanced non-small cell lung cancer (NSCLC) patients carrying …

Simple Summary Epidermal growth factor receptor (EGFR) mutations occur in a significant
number of lung cancer patients. Treatment outcomes in this subset of patients has greatly …

Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …

Lung cancer is managed using conventional therapies, including chemotherapy, radiation
therapy, or a combination of both. Each of these therapies has its own limitations, such as …

Epidermal growth factor receptor (EGFR) mutations are the most common oncogenic drivers
in non-small-cell lung cancer (NSCLC). Significant developments have taken place which …

Simple Summary The management of non-small cell lung cancer with a common EGFR
mutation has evolved over the past decades. While frontline use of second-or third …

Living guidelines are developed for selected topic areas with rapidly evolving evidence that
drives frequent change in recommended clinical practice. Living guidelines are updated on …

Epidermal growth factor receptor (EGFR), a critical factor promotes lung cancer cell
proliferation and survival. Knockdown of EGFR expression thus promise beating lung cancer …

Objectives The goal of this study was to evaluate the effectiveness of radiomics signatures
on pre-treatment computed tomography (CT) images of lungs to predict the tumor responses …